About the programme
Despite the prevalence of cancer in the elderly and progress in biomedical and technological research on the topic, it is still complicated to provide a treatment adapted to this patient population. Many clinical trials do indeed exclude the elderly from their cohort due to the higher number of risk factors or underlying conditions concentrated in that population. That exclusion leads to a shortage of data and recommendations in geriatric oncological treatments to the extent that the situations of under- or over-treatment of these patients is commonplace. Given that the French population is ageing, these issues are becoming a major public health concern.
The aim of PrIME is to combine multidisciplinary approaches to improve the care of geriatric cancers patients using individualised treatments and methods.
Pierre Soubeyran, Muriel Rainfray and Carine Bellera jointly coordinate all the research for the PrIME project within BRIO, in constant cooperation with the programme manager. They define PrIME’s major strategic preclinical and clinical research fields, in accordance with the budget as well as the medical and competitive environment. They co-host the programme’s biannual progress meetings as well as the meetings to prepare for the international Scientific Advisory Board (SAB).
Within the framework of PrIME, several clinical studies are underway, such as :
* PREPARE, a multicentric phase III including a total of 1500 patients in France comparing conventional care management of elderly cancer patients with geriatric intervention, and the PRIORITY study assessing the evolution of priorities of patients treated with chemotherapy before and after three months of treatment. (NCT02704832)
*PRIORITY (observational phase IV, elderly cancer patients NCT02821793)
*BANCO (clinical/biological data collection of elderly cancer patients NCT02704832)
*REALYSA (observational phase IV, NCT03869619)